Hypomania associated with high dose ketamine treatment
- 15 February 2021
- journal article
- editorial
- Published by Wiley in Bipolar Disorders
- Vol. 23 (4) , 426-428
Abstract
For more than 50 years, pharmacotherapy for major depressive disorder (MDD) has narrowly focused on enhancing monoaminergic neurotransmission resulting in more than 30 FDA‐ approved treatments. In contrast, the glutamatergic, non‐competitive N‐methyl D‐aspartate (NMDA) receptor antagonist ketamine has been “repurposed” as a rapid acting antidepressant1; the enantiomer S‐ketamine, or esketamine, is now FDA‐approved for treatment resistant unipolar depression (TRD).Keywords
This publication has 4 references indexed in Scilit:
- A report of affective switching associated with ketamine: The case of ketamine‐induced mania is not closedBipolar Disorders, 2018
- Potential Risks of Poorly Monitored Ketamine Use in Depression TreatmentAmerican Journal of Psychiatry, 2016
- A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive DisorderBiological Psychiatry, 2014
- Lack of Mania Prophylaxis Associated With Lamotrigine Monotherapy in Manic-Predominant Bipolar I DisorderThe Journal of Clinical Psychiatry, 2007